SCHEMBL6499147

SCHEMBL6499147

Cc1ccc(C2=C(C(=O)Nc3ccc(N4CCN(Cc5ccc(C#N)cc5)CC4)cc3)CCCC2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.46
TSHR P16473 1/20 0.46
MAPK1 P28482 1/20 0.46
FAAH O00519 1/20 0.46
PRKAA2 P54646 1/20 0.45
LMNA P02545 4/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
KMT2A Q03164 2/20 0.44
HSD17B10 Q99714 2/20 0.44
ACHE P22303 1/20 0.44
NPC1 O15118 3/20 0.43
RAB9A P51151 3/20 0.43
KDM4E B2RXH2 1/20 0.43
MEN1 O00255 1/20 0.43
MCL1 Q07820 1/20 0.43
MAP4K4 O95819 1/20 0.42
NTRK1 P04629 1/20 0.42
FLT3 P36888 1/20 0.42
KCNA5 P22460 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6491504 0.91 FAAH (0.49) MAPTTSHRMAPK1FAAHPRKAA2
SCHEMBL6498772 0.89 MAPT (0.58) MAPTTSHRMAPK1FAAHLMNA
SCHEMBL6504210 0.85 KMT2A (0.45) MAPTTSHRMAPK1LMNASMN1; SMN2
SCHEMBL6502650 0.81 MAPT (0.47) MAPTMAPK1LMNASMN1; SMN2L3MBTL1
SCHEMBL6499900 0.80 DRD2 (0.46) MAPTTSHRMAPK1LMNASMN1; SMN2
SCHEMBL6488692 0.80 SLC2A1 (0.52) MAPTFAAHPRKAA2LMNASMN1; SMN2
SCHEMBL6499989 0.80 NPC1 (0.53) MAPTMAPK1LMNASMN1; SMN2L3MBTL1
SCHEMBL6489230 0.79 PRKAA2 (0.47) MAPTFAAHPRKAA2L3MBTL1RAB9A
SCHEMBL6492454 0.78 MAPT (0.41) MAPTTSHRMAPK1LMNASMN1; SMN2
SCHEMBL6490476 0.78 MEN1 (0.42) MAPTTSHRMAPK1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors DAISO CO., LTD. (JP) 2005-02-17 US disclosed
EP-1472226-A1 HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-11-03 EP disclosed
WO-2003045921-A1 HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors APOB, APOL1, CTRB2 MAPT 4202/4885TSHR 2021/4885MAPK1 1923/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.